Novartis Pharma AG 13D/13G Filings for CELLULAR BIOMEDICINE GROUP, IN (CBMG)

Novartis Pharma AG 13D and 13G filings for CELLULAR BIOMEDICINE GROUP, IN:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2021-02-23
7:57 pm
Sale
2021-02-1913DCELLULAR BIOMEDICINE GROUP, IN
CBMG
Novartis Pharma AG0
0.000%
-1,458,257decrease
(Position Closed)
Filing